Bluesky Facebook Reddit Email

Public opinion on transparency at the FDA

02.18.22 | JAMA Network

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

What The Study Did: Public support for or opposition to transparency measures regarding the Food and Drug Administration (FDA) drug approval process was assessed in this survey study.

Authors: Joshua M. Sharfstein, M.D., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.0026)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.0026?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=021822

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

JAMA Network Open

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2022, February 18). Public opinion on transparency at the FDA. Brightsurf News. https://www.brightsurf.com/news/8Y4J69OL/public-opinion-on-transparency-at-the-fda.html
MLA:
"Public opinion on transparency at the FDA." Brightsurf News, Feb. 18 2022, https://www.brightsurf.com/news/8Y4J69OL/public-opinion-on-transparency-at-the-fda.html.